SLCO1A2 and neoplasm: For example, researchers are developing tumor-targeted microcystin conjugates (linking the toxin to tumor-seeking carriers like antibodies or nanoparticles) to treat OATP-expressing malignancies such as liver and pancreatic cancers [14,16].